Aspirin plus dipyridamole was more effective than aspirin alone for preventing vascular events after minor cerebral ischaemia

نویسندگان

چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Aspirin plus dipyridamole was more effective than aspirin alone for preventing vascular events after minor cerebral ischemia.

M e t h o d s Design: Randomized controlled trial (European/Australasian Stroke Prevention in Reversible Ischaemia Trial [ESPRIT]). Allocation: Concealed.* Blinding: Blinded (outcome auditing committee).* Follow-up period: Mean 3.5 years. Setting: 79 hospitals in Europe, Singapore, Australia, and the United States. Patients: 2763 patients (mean age 63 y, 65% men) who had had a minor ischemic st...

متن کامل

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial

Methods We did a randomised controlled trial in which we assigned patients to aspirin (30–325 mg daily) with (n=1363) or without (n=1376) dipyridamole (200 mg twice daily) within 6 months of a transient ischaemic attack or minor stroke of presumed arterial origin. Our primary outcome event was the composite of death from all vascular causes, non-fatal stroke, non-fatal myocardial infarction, or...

متن کامل

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.

BACKGROUND Results of trials of aspirin and dipyridamole combined versus aspirin alone for the secondary prevention of vascular events after ischaemic stroke of presumed arterial origin are inconsistent. Our aim was to resolve this uncertainty. METHODS We did a randomised controlled trial in which we assigned patients to aspirin (30-325 mg daily) with (n=1363) or without (n=1376) dipyridamole...

متن کامل

Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease.

BACKGROUND Aspirin is the prophylactic antiplatelet drug of choice for people with cardiovascular disease. However, protection with antiplatelet therapy in people with a high risk of cardiovascular disease is unsatisfactory in absolute terms. Adding a second antiplatelet drug to aspirin may produce additional benefit for those at high risk and those with established cardiovascular disease. OB...

متن کامل

Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation.

M e t h o d s Design: Randomized controlled trial (Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events [ACTIVE W]). Allocation: Concealed.* Blinding: Blinded (outcome assessors and monitoring committee).* Follow-up period: Median 1.28 years. Setting: 30 clinical centers worldwide. Patients: 6706 patients (mean age 70 y, 66% men) with AF and ≥ 1 of the followi...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Evidence-Based Medicine

سال: 2006

ISSN: 1356-5524

DOI: 10.1136/ebm.11.6.169